After the announced closure of CureVac by BioNTech, the Tübingen site is likely to be largely closed. An employee reports on idleness and a lot of uncertainty.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
After the announced closure of CureVac by BioNTech, the Tübingen site is likely to be largely closed. An employee reports on idleness and a lot of uncertainty.